Last reviewed · How we verify

CimetrA-1 — Competitive Intelligence Brief

CimetrA-1 (CimetrA-1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid therapeutic. Area: Neurology / Immunology.

phase 3 Cannabinoid therapeutic Neurology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CimetrA-1 (CimetrA-1) — MGC Pharmaceuticals d.o.o. CimetrA-1 is a cannabinoid-based therapeutic that modulates endocannabinoid system signaling to produce anti-inflammatory and neuroprotective effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CimetrA-1 TARGET CimetrA-1 MGC Pharmaceuticals d.o.o phase 3 Cannabinoid therapeutic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid therapeutic class)

  1. MGC Pharmaceuticals d.o.o · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CimetrA-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/cimetra-1. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: